Trial · NCT03148275
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Objective Response Rate | 6 months | Percentage | NUMBER | |
| SECONDARY | 6 Month Progression-free Survival | From time of first dose of study medication to occurrence of radiologic tumor progression per Response Evaluation Criteria in Solid Tumors 1.1, clinical progression based on treating physician assessment or death from any cause, assessed at 6 months | percentage of participants | NUMBER | |
| SECONDARY | Overall Survival | From the time of first dose of study drug to occurrence of death from any cause, assessed at 2 years | Percentage | NUMBER | |
| SECONDARY | Incidence of Adverse Events | at 6 months | participants who experienced the event | NUMBER | |
| SECONDARY | Change in Patient Reported Symptoms | Baseline and at 6 months | as participants were removed from trial, the number of completed PROMIS forms decreased | T Score | MEAN |
| SECONDARY | Median Progression-free Survival | From time of first dose of study medication to occurrence of radiologic tumor progression per Response Evaluation Criteria in Solid Tumors 1.1, clinical progression based on treating physician | months | MEDIAN | |
| OTHER_PRE_SPECIFIED | Change in Epithelioid Hemangioendothelioma Growth Rate | Baseline up to 6 months | |||
| OTHER_PRE_SPECIFIED | Change in CRP Level | Baseline up to 6 months | |||
| OTHER_PRE_SPECIFIED | Change in ESR Level | Baseline up to 6 months | |||
| OTHER_PRE_SPECIFIED | Change in Plasma CTGF Level | Baseline up to 6 months | |||
| OTHER_PRE_SPECIFIED | Change in Tumor Volume | Baseline up to 6 months | |||
| OTHER_PRE_SPECIFIED | Number of TAZ-CAMTA1 Gene Fusion | Up to 6 months | |||
| OTHER_PRE_SPECIFIED | Percent of TAZ-CAMTA1 Gene Fusion | Up to 6 months | |||
| OTHER_PRE_SPECIFIED | MAP Kinase Activation | Up to 6 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03148275/outcomes